natgillin/translations-raw huggingface dataset:
Because you are using this medicine for COPD, you may be at an increased risk of developing an infection of the lungs known as pneumonia. 
Ker uporabljate to zdravilo za KOPB, imate morda večje tveganje za okužbo pljuč, imenovano pljučnica.
A decision must be made whether to discontinue breast-feeding or to discontinue Trelegy Ellipta therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje zdravljenja z zdravilom Trelegy Ellipta, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
Umeclidinium and vilanterol belong to a group of medicines called bronchodilators. 
Umeklidinij in vilanterol spadata v skupino zdravil, imenovanih bronhodilatatorji.
You may notice that your heart is beating faster than usual, you feel shaky, you have visual disturbances, have a dry mouth, or have a headache. 
Opazite lahko hitrejše bitje srca kot po navadi, občutek drhtenja, motnje vida, suha usta ali glavobol.
These patients may have also been taking other COPD medications (e.g. mucolytics or leukotriene receptor antagonists). 
Ti bolniki so lahko uporabljali tudi druga zdravila za KOPB (npr. mukolitike ali antagoniste levkotrienskih receptorjev).
Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. 
Zvišanje ravni cikličnega AMP povzroča sprostitev bronhialnih gladkih mišic in zavre sproščanje mediatorjev takojšnje preobčutljivosti iz celic, predvsem iz mastocitov.
The precise mechanism through which fluticasone furoate affects COPD symptoms is not known. 
Natančen mehanizem, po katerem flutikazonfuroat vpliva na simptome KOPB, ni znan.
In vitro protein binding studies between subjects with severe renal impairment and healthy volunteers were conducted, and no clinically significant evidence of altered protein binding was seen. 
In vitro so izvedli študije vezave na beljakovine pri bolnikih s hudo okvaro ledvic in zdravih prostovoljcih; te študije niso pokazale klinično pomembnih znakov spremenjene vezave na beljakovine.
Trelegy Ellipta should not be used in patients with asthma since it has not been studied in this patient population. 
Zdravila Trelegy Ellipta se ne sme uporabljati pri bolnikih z astmo, ker v tej populaciji bolnikov ni raziskano.
• infection of the nose, sinuses or throat 
• okužba nosu, obnosnih votlin (sinusov) ali grla,
For the 14-dose inhaler, the dose counter will also show half red when there are fewer than 10 doses left, and then will show half red with the number 0 after the last dose is used. 
Na inhalatorju s 14 odmerki bo pol števca odmerkov rdečega, ko bo preostalo manj kot 10 odmerkov, po uporabi zadnjega odmerka pa bo postal popolnoma rdeč in pokazal bo številko 0.
Co-administration should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid adverse reactions, in which case patients should be monitored for systemic corticosteroid adverse reactions. 
Sočasni uporabi se je treba izogniti, razen če korist odtehta povečano tveganje za pojav sistemskih neželenih učinkov kortikosteroidov; v tem primeru je treba bolnike nadzorovati glede sistemskih neželenih učinkov kortikosteroidov.
However, these higher systemic exposures remain below the threshold for FF-induced reduction of serum and urine cortisol and are not considered clinically relevant. 
Vendar so bile te visoke sistemske izpostavljenosti pod pragom, nad katerim FF zniža raven kortizola v serumu in urinu in se ne smatrajo za klinično pomembne.
Patients should not stop therapy with Trelegy Ellipta without physician supervision since symptoms may recur after discontinuation. 
Bolniki ne smejo končati zdravljenja z zdravilom Trelegy Ellipta brez zdravniškega nadzora, ker se lahko simptomi po prenehanju zdravljenja ponovijo.
NAME OF THE MARKETING AUTHORISATION HOLDER GlaxoSmithKline Trading Services Limited GSK Logo 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM GlaxoSmithKline Trading Services Limited GSK logo
In terms of other patient characteristics, a study in CYP2D6 poor metabolisers showed no evidence of a clinically significant effect of CYP2D6 genetic polymorphism on systemic exposure to umeclidinium. 
Kar zadeva druge značilnosti bolnikov, študija slabih metabolizatorjev s CYP2D6 ni pokazala klinično pomembnega vpliva genetskega polimorfizma CYP2D6 na sistemsko izpostavljenost umeklidiniju.
• sore, raised patches in the mouth or throat caused by a fungal infection (candidiasis). 
• boleče, dvignjene lehe v ustih ali žrelu, ki jih povzroča glivična okužba (kandidoza).
There are no clinical data to support the use of Trelegy Ellipta for the treatment of acute episodes of bronchospasm, or to treat an acute COPD exacerbation (i.e. as a rescue therapy). 
Ni kliničnih podatkov, ki bi potrjevali uporabo zdravila Trelegy Ellipta za zdravljenje akutnega bronhospazma ali akutnega poslabšanja KOPB (tj. za rešilno zdravljenje).
The most frequently reported adverse reactions with Trelegy Ellipta were nasopharyngitis (7%), headache (5%) and upper respiratory tract infection (2%). 
Najpogosteje zabeleženi neželeni učinki med uporabo zdravila Trelegy Ellipta so bili nazofaringitis (7 %), glavobol (5 %) in okužba zgornjih dihal (2 %).
The other ingredients are lactose monohydrate (see section 2 under ‘Trelegy Ellipta contains lactose') and magnesium stearate. 
Pomožni snovi sta laktoza monohidrat (glejte poglavje 2 pod naslovom "Zdravilo Trelegy Ellipta vsebuje laktozo") in magnezijev stearat.
Population PK analyses for FF/UMEC/VI were conducted using a combined PK dataset from three phase III studies in 821 COPD subjects. 
Populacijske farmakokinetične analize FF/UMEC/VI so izvedli s kombiniranim naborom farmakokinetičnih podatkov iz treh študij III. faze na 821 preiskovancih s KOPB.
Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g. eosinophils, macrophages, lymphocytes) and mediators (e.g. cytokines and chemokines) involved in inflammation. 
Dokazano je, da imajo kortikosteroidi širok spekter vplivov na več vrst celic (npr. na eozinofilce, makrofage, limfocite) in mediatorjev (npr. na citokine in kemokine), ki sodelujejo pri vnetju.
Not all pack sizes may be available in your country. 
V vaši državi na trgu morda ni vseh navedenih pakiranj.
other long-acting medicines similar to this medicine that are used to treat breathing problems, e.g. 
druga dolgodelujoča zdravila, podobna temu zdravilu, ki se uporabljajo za zdravljenje težav z dihanjem, npr. tiotropij, indakaterol.
Tabulated summary of adverse reactions The safety profile of Trelegy Ellipta is based on three phase III clinical studies. 
Povzetek neželenih učinkov v preglednici Ugotovljene varnostne značilnosti zdravila Trelegy Ellipta temeljijo na treh kliničnih študijah III. faze.
The effect of the moderate P-gp inhibitor verapamil (240 mg once daily) on the steady-state pharmacokinetics of umeclidinium and vilanterol was assessed in healthy volunteers. 
Vpliv zmernega zaviralca P-gp verapamila (v odmerku 240 mg enkrat na dan) na farmakokinetiko umeklidinija in vilanterola v stanju dinamičnega ravnovesja so ocenili pri zdravih prostovoljcih.
Significant reductions were observed over all other timepoints for UMEC/VI (p<0.001) and for the all but two of the of timepoints for FF/VI (p≤0.021). 
Značilno zmanjšanje je bilo opaženo na vseh drugih časovnih točkah za UMEC/VI (p < 0,001) in na vseh časovnih točk razen dveh za FF/VI (p ≤ 0,021).
Interaction with CYP3A4 inhibitor 
Medsebojno delovanje z zaviralci CYP3A4
It is not possible to accidentally take extra medicine or a double dose in one inhalation. 
Pri eni inhalaciji ni mogoče pomotoma uporabiti dodatne količine zdravila ali dvojnega odmerka.
When you take the inhaler out of the sealed tray, it will be in the ‘closed' position. 
Ko vzamete inhalator iz embalaže, bo v položaju "zaprto".
No clinically relevant effects requiring dose adjustment were observed. 
Pokazala ni nobenih klinično pomembnih vplivov, ki bi zahtevali prilagoditev odmerka.
Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). 
Flutikazonfuroat, umeklidinij in vilanterol so substrati P-glikoproteinskega prenašalca (P-gp).
Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures. 
Kardioselektivna blokada beta pride v poštev le pri zelo izrazitih učinkih prevelikega odmerjanja vilanterola, ki so klinično zaskrbljujoči in se ne odzovejo na podporne ukrepe.
It should not be used to relieve a sudden attack of breathlessness or wheezing. 
Ne smete ga uporabljati za olajšanje nenadnega napada težkega dihanja ali piskanja.
Fluticasone furoate is a corticosteroid with potent anti-inflammatory activity. 
Flutikazonfuroat je kortikosteroid z močnim protivnetnim delovanjem.
The inhaler contains two aluminium foil laminate blister strips that deliver a total of 14 or 30 doses (14 or 30 day supply). 
Inhalator vsebuje dva pretisna trakova iz laminata aluminijske folije, ki oddata skupno 14 ali 30 odmerkov (14- ali 30-dnevna zaloga).
Each inhaler contains either 14 or 30 doses (14 or 30 day supply). 
Vsak inhalator vsebuje 14 ali 30 odmerkov (zaloga za 14 ali 30 dni).
An approximately 1.4-fold increase in umeclidinium AUC was observed with no effect on vilanterol AUC. 
Opazili so približno 1,4-kratno povečanje AUC umeklidinija in nobenega vpliva na AUC vilanterola.
Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products) as there is potential for increased systemic exposure to both fluticasone furoate and vilanterol, which could lead to an increased potential for adverse reactions. 
Previdnost je potrebna med sočasno uporabo z močnimi zaviralci CYP3A4 (npr. ketokonazol, ritonavir, zdravila, ki vsebujejo kobicistat), ker obstaja možnost večje sistemske izpostavljenosti flutikazonfuroatu in vilanterolu, to pa lahko poveča možnost neželenih učinkov.
Once the tray is opened Trelegy Ellipta is ready to use. 
Ko je embalaža odprta, je zdravilo Trelegy Ellipta pripravljeno za uporabo.
Trelegy Ellipta is for inhalation use only. 
Zdravilo Trelegy Ellipta je namenjeno samo za inhalacijsko uporabo.
The recommended and maximum dose is one inhalation of Trelegy Ellipta 92/55/22 micrograms once daily, at the same time each day. 
Priporočeni in največji odmerek je ena inhalacija zdravila Trelegy Ellipta 92/55/22 mikrogramov enkrat na dan, vsak dan ob istem času.
Adverse reactions detected during these clinical trials are listed by MedDRA system organ class. 
Neželeni učinki, ki so jih ugotovili v teh kliničnih preskušanjih, so prikazani po organskih sistemih po MedDRA.
An overdose will likely produce signs, symptoms or adverse effects associated with the individual components' pharmacological actions (e.g. Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, dry mouth, visual accommodation disturbances, tachycardia, arrhythmias, tremor, headache, palpitations, nausea, hyperglycaemia and hypokalaemia). 
Preveliko odmerjanje bo verjetno povzročilo znake, simptome ali neželene učinke, povezane s farmakološkim delovanjem posameznih sestavin (npr. Cushingov sindrom, cushingoidne značilnosti, zavrtje nadledvičnih žlez, zmanjšanje mineralne gostote kosti, suhost ust, motnje akomodacije vida, tahikardijo, motnje srčnega ritma, tremor, glavobol, palpitacije, navzeo, hiperglikemijo in hipokaliemijo).
Beta2-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol. 
Antagonisti adrenergičnih receptorjev beta2 lahko oslabijo ali antagonizirajo učinek agonistov adrenergičnih receptorjev beta2, kakršen je vilanterol.
• Take one long, steady, deep breath in. 
• Naredite en dolg, enakomeren, globok vdih.
Therefore, caution is advised in moderate to severe hepatic impairment, but no specific dose adjustment based on hepatic function is recommended. 
Zato je pri bolnikih z zmerno do hudo okvaro jeter potrebna previdnost, vendar pa niso priporočene specifične prilagoditve odmerka glede na delovanje jeter.
Umeclidinium is a long-acting muscarinic receptor antagonist (also referred to as an anticholinergic). 
Umeklidinij je dolgodelujoč antagonist muskarinskih receptorjev (imenovanih tudi antiholinergiki).
Caution should be exercised when Trelegy Ellipta is used with other medicinal products that also have the potential to cause hypokalaemia (see section 4.5). 
Previdnost je potrebna, če se zdravilo Trelegy Ellipta uporablja z drugimi zdravili, ki lahko prav tako povzročijo hipokaliemijo (glejte poglavje 4.5).
Urinary excretion accounted for approximately 2 % of the intravenously administered dose. 
Na račun izločanja v urinu je šlo približno 2 % intravensko uporabljenega odmerka.
The mouthpiece should be placed between the lips and the lips should then be closed firmly around it. 
Bolnik naj ustnik namesti med ustnici in ju nato trdno stisne okrog njega.
For fluticasone furoate, patients with moderate hepatic impairment showed up to three times higher systemic exposure (FF 184 micrograms); therefore, patients with severe hepatic impairment received half the dose (FF 92 micrograms). 
Sistemska izpostavljenost flutikazonfuroatu je bila pri bolnikih z zmerno okvaro jeter do trikrat večja (184 mikrogramov FF), zato so bolniki s hudo okvaro jeter prejeli polovico odmerka (92 mikrogramov FF).
Treatment difference 95% CI 
Razlika med zdravljenjema (95% IZ)
The fluticasone furoate/vilanterol component of Trelegy Ellipta was assessed in patients with all severities of hepatic impairment (Child-Pugh A, B or C). 
Sestavini flutikazonfuroat/vilanterol zdravila Trelegy Ellipta so ocenili pri bolnikih z vsemi stopnjami okvare jeter (Child-Pugh A, B in C).
Table 2 - Lung function endpoint in IMPACT 
Preglednica 2 - Opazovani dogodek pljučne funkcije v študiji IMPACT
The increase in vilanterol exposure was not associated with an increase in beta2-agonist related systemic effects on heart rate or blood potassium. 
Večje izpostavljenosti vilanterolu ni spremljalo povečanje z agonistom adrenergičnih receptorjev beta2 povezanih sistemskih učinkov na srčno frekvenco ali raven kalija v krvi.
The primary metabolic route for fluticasone furoate is hydrolysis of the S-fluoromethyl carbothioate group to metabolites with significantly reduced corticosteroid activity. 
Primarna pot presnove flutikazonfuroata je hidroliza S-fluorometilkarbotioatne skupine v presnovke, ki imajo bistveno manjše kortikosteroidno delovanje.
Vilanterol was not teratogenic in rats. 
Vilanterol pri podganah ni bil teratogen.
Interaction with CYP2D6 inhibitors/CYP2D6 polymorphism 
Medsebojno delovanje z zaviralci CYP2D6/polimorfizem CYP2D6
Following intravenous administration, the elimination phase half-life averaged 15.1 hours. 
Povprečni razpolovni čas eliminacijske faze je bil po intravenski uporabi 15,1 ure.
It is unlikely that this medicine will affect your ability to drive or use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi to zdravilo vplivalo na vašo sposobnost za upravljanje vozil in strojev.
Upon initiation of treatment with Trelegy Ellipta, plasma glucose should be monitored more closely in diabetic patients. 
Po uvedbi zdravljenja z zdravilom Trelegy Ellipta je treba sladkornim bolnikom natančneje kontrolirati glukozo v plazmi.
If you become wheezy or breathless, use your quick-acting inhaler (such as salbutamol), then seek medical advice. 
Če se vam pojavi piskajoče ali težko dihanje, uporabite svoj hitrodelujoč inhalator (npr. salbutamol) in nato poiščite zdravniški nasvet.
Slide the cover upwards as far as it will go, to cover the mouthpiece. 
Pokrovček mora potisniti navzgor, kolikor daleč gre, da pokrije ustnik.
Umeclidinium has not been evaluated in patients with severe hepatic impairment. 
Umeklidinija niso ocenili pri bolnikih s hudo okvaro jeter.
Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta2-adrenergic agonists, therefore caution should be exercised (see section 4.4). 
Sočasno hipokaliemično zdravljenje z metilksantinskimi derivati, steroidi ali diuretiki, ki ne ohranjajo kalija, lahko stopnjuje možni hipokaliemični učinek agonistov adrenergičnih receptorjev beta2, zato je potrebna previdnost (glejte poglavje 4.4).
The mouthpiece of the inhaler may be cleaned using a dry tissue before closing the cover. 
Ustnik inhalatorja lahko očisti s suho krpico, preden zapre pokrovček.
The air vents should not be blocked with fingers during use. 
Med uporabo ne sme s prsti prekriti rež za zrak.
If beta-blockers are required, cardioselective beta-blockers should be considered, however, caution should be exercised during concurrent use of both non-selective and selective beta-blockers. 
Če obstaja potreba po uporabi antagonistov beta, je treba razmisliti o uporabi kardioselektivnih antagonistih beta, vendar pa je med sočasno uporabo potrebna previdnost; to velja tako za selektivne kot za kardioselektivne antagoniste beta.
Slide the cover down fully until a “click” is heard. 
Pokrovček mora potisniti navzdol, dokler se ne zasliši "klik".
At study entry, the most common COPD medications reported in the FULFIL and IMPACT studies were ICS +LABA+LAMA (28%, 34% respectively), ICS+LABA (29%, 26% respectively), LAMA+LABA (10%, 8% respectively) and LAMA (9%, 7% respectively). 
Ob vstopu v študiji FULFIL in IMPACT so bila najpogostejša zdravila za KOPB, o katerih so poročali v študijah IGK + LABA + LAMA (FULFIL 28 % in IMPACT 34 %), IGK + LABA (29 % in 26 %), LAMA + LABA (10 % in 8 %) in LAMA (9 % in 7 %).
Do not throw away any medicines via household waste. 
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
The medicine may not be tasted or felt, even when using the inhaler correctly. 
Zdravila morda ne bo ne okusil ne občutil, tudi če inhalator uporablja pravilno.
All three studies were multicentre, randomised, double-blind studies that required patients to be symptomatic with a COPD Assessment Test (CAT) score ≥10 and on daily maintenance treatment for their COPD for at least three months prior to study entry. 
Bolniki so morali biti simptomatski in ocenjeni z oceno 10 ali več po testu za oceno KOPB (COPD Assessment Test, CAT) ter so morali prejemati vsakodnevno vzdrževalno zdravljenje za KOPB vsaj tri mesece pred vstopom v študijo.
The “Discard by” date is 6 weeks from the date you open the tray. 
Datum "Zavrzite do" je 6 tednov od datuma, ko ste odprli embalažo.
Step-by-step instructions 
Navodila po korakih
Your doctor may wish to monitor you carefully if you are taking any of these medicines as they may increase the side effects of Trelegy Ellipta. 
Če jemljete katero od teh zdravil, vas bo zdravnik morda natančno nadzoroval, kajti ta zdravila lahko povečajo neželene učinke zdravila Trelegy Ellipta.
If you use more Trelegy Ellipta than you should 
Če ste uporabili večji odmerek zdravila Trelegy Ellipta, kot bi smeli
Don't block the air vent with your fingers. 
Pazite, da ne boste s prsti prekrili rež za zrak.
This medicine widens these muscles in the lungs, reducing the swelling and irritation in the small air passages and making it easier for air to get in and out of the lungs. 
Zdravilo Trelegy Ellipta sprosti te mišice v pljučih, zmanjša oteklost in draženje v malih dihalnih poteh ter olajša vstopanje zraka v pljuča in njegovo izstopanje iz pljuč.
If the inhaler cover is opened and closed without inhaling the medicinal product, the dose will be lost. 
Če se pokrovček inhalatorja odpre in zapre, ne da bi bilo zdravilo vdihnjeno, bo odmerek zdravila izgubljen.
Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Trelegy Ellipta and to contact their doctor immediately should any of these signs or symptoms develop. 
Bolnike je treba seznaniti z znaki in simptomi akutnega glavkoma z ozkim zakotjem; naročiti jim je treba, da morajo v primeru takšnih znakov ali simptomov nemudoma prenehati uporabljati zdravilo Trelegy Ellipta in se posvetovati z zdravnikom.
PHARMACEUTICAL FORM AND CONTENTS Inhalation powder, pre-dispensed 1 inhaler of 30 doses. 
FARMACEVTSKA OBLIKA IN VSEBINA Prašek za inhaliranje, odmerjeni 1 inhalator s 30 odmerki.
Umeclidinium is a substrate of cytochrome P450 2D6 (CYP2D6). 
Umeklidinij je substrat citokroma P450 2D6 (CYP2D6).
Keep the inhaler inside the sealed tray to protect from moisture and only remove immediately before first use. 
Inhalator naj ostane v zaprti embalaži za zagotovitev zaščite pred vlago in ga vzemite iz nje šele tik pred prvo uporabo.
The steady-state pharmacokinetics of umeclidinium was assessed in healthy volunteers lacking CYP2D6 (poor metabolisers). 
Farmakokinetiko umeklidinija v stanju dinamičnega ravnovesja so ocenili pri zdravih prostovoljcih s pomanjkanjem CYP2D6 (slabi metabolizatorji).
The absolute bioavailability of fluticasone furoate when administrated as fluticasone furoate/vilanterol by inhalation was 15.2%, primarily due to absorption of the inhaled portion of the dose delivered to the lung, with negligible contribution from oral absorption. 
Absolutna biološka uporabnost flutikazonfuroata, uporabljenega v kombinaciji flutikazonfuroat/vilanterol v inhalaciji, je bila 15,2 %, predvsem zaradi absorpcije vdihanega dela odmerka, ki je prišel v pljuča; prispevek peroralne absorpcije je bil zanemarljiv.
Each blister in one strip contains fluticasone furoate, each blister in the other strip contains umeclidinium (as bromide) and vilanterol (as trifenatate). 
Vsak pretisni del na enem traku vsebuje flutikazonfuroat in vsak pretisni del na drugem traku vsebuje umeklidinij (kot bromid) in vilanterol (kot trifenatat).
Pharmacological and toxicological effects seen with fluticasone furoate, umeclidinium or vilanterol in nonclinical studies were those typically associated with glucocorticoids, muscarinic receptor antagonists, or beta2-adrenergic receptor agonists. 
Farmakološki in toksikološki učinki, ki so jih s flutikazonfuroatom, umeklidinijem ali vilanterolom zabeležili v nekliničnih študijah, so bili takšni, kot tipično spremljajo glukokortikoide, antagoniste muskarinskih receptorjev ali agoniste adrenergičnih receptorjev beta2.
Administration of fluticasone furoate/umeclidinium/vilanterol may produce paradoxical bronchospasm with an immediate wheezing and shortness of breath after dosing and may be life-threatening. 
Uporaba flutikazonfuroata/umeklidinija/vilanterola lahko povzroči paradoksni bronhospazem - pojav piskajočega dihanja in kratke sape takoj po uporabi zdravila - ki je lahko smrtno nevaren.
It demonstrates slow reversibility at the human M3 muscarinic receptor subtype in vitro and a long duration of action in vivo when administered directly to the lungs in pre-clinical models. 
Na podtipu M3 človeških muskarinskih receptorjev in vitro je njegovo delovanje počasi reverzibilno, in vivo pa je dolgotrajno, če je v predkliničnih modelih uporabljen neposredno na pljučih.
• Inhale with one long, steady, deep breath in. 
• Vdihne naj z enim dolgim, enakomernim, globokim vdihom.
Pneumonia which required hospitalisation occurred in 1% of patients receiving Trelegy Ellipta and <1% of patients receiving budesonide/formoterol up to 24 weeks. 
Pljučnica, ki je zahtevala sprejem v bolnišnico, se je v obdobju do 24 tednov pojavila pri 1 % prejemnikov zdravila Trelegy Ellipta in pri < 1 % prejemnikov kombinacije budezonid/formoterol.
Patients with moderate hepatic impairment showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (Cmax and AUC). 
Pri bolnikih z zmerno okvaro jeter niso ugotovili znakov večje sistemske izpostavljenosti umeklidiniju ali vilanterolu (Cmax in AUC).